+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pentoxifylline does not prevent cytokine induced first dose reactions following therapy of acute renal transplant rejection with OKT3



Pentoxifylline does not prevent cytokine induced first dose reactions following therapy of acute renal transplant rejection with OKT3



Nephrology Dialysis Transplantation 10(6): 1070




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032747836

Download citation: RISBibTeXText


Related references

Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study. Transplantation 61(4): 573-577, 1996

High or low dose steroid therapy for acute renal transplant rejection after prophylactic OKT3 treatment: a prospective randomized study. Transplant International 5(Suppl. 1): S437, 1992

High or low dose steroid therapy for acute renal transplant rejection after prophylactic Okt3 treatment: a prospective randomized study. Transplant International 5: S437-S439, 1992

Concomitant low-dose cyclosporine and OKT3 therapy for renal transplant rejection. Transplantation Proceedings 21(1 Pt 2): 1755-1757, 1989

Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients. Transplantation Proceedings 25(4): 2574, 1993

Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection. Transplantation 55(3): 677-679, 1993

Pure anti t cell therapy okt3 may fail to reverse acute rejection of a cadaveric renal transplant. Kidney International 33(1): 447, 1988

A retrospective analysis of the effect of indomethacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection. American Journal of Kidney Diseases 24(3): 486-490, 1994

Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients. Transplantation Proceedings 30(2): 285-287, 1998

Single-center analysis of the incidence of acute rejection in cadaveric renal allograft recipients induced with low-dose OKT3 with and without mycophenolate mofetil. Transplantation Proceedings 31(5): 2112-2113, 1999

Uveitis associated with OKT3 therapy for renal transplant rejection. British Journal of Ophthalmology 85(4): 500-501, 2001

A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transplant International 11(3): 231-236, 1998

Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplantation Proceedings 25(1 Pt 1): 561-563, 1993

OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplantation Proceedings 27(1): 873-874, 1995

The use of outpatient OKT3 for renal transplant rejection is both cost-effective and safe as compared to inpatient OKT3 use. Clinical and Investigative Medicine 20(4 Suppl. ): S106, 1997